Is capmatinib included in the reimbursement scope of my country's medical insurance?

Capmatinib (Capmatinib) is a MET inhibitor, mainly used to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. In recent years, with the accelerated approval of targeted drugs in my country, capmatinib has been successfully launched in China and included in the national medical insurance directory, which has greatly reduced the financial burden for patients who require long-term medication.

Although capmatinib has been included in medical insurance, due to its short time on the market, it is still not available in hospitals or pharmacies in some areas. Therefore, it is difficult for some patients to purchase in the country. However, as time goes by and the drug circulation and supply system gradually improves, it will be more convenient and stable to obtain capmatinib domestically in the future.

In response to the problem of limited purchasing channels, some patients also choose to obtain drugs through overseas channels. In overseas markets, the price of the original drug capmatinib is generally high, and the price of each box of the drug may be as high as tens of thousands of yuan, which is a great pressure for patients with limited financial conditions. Fortunately, there are currently generic capmatinib drugs produced in Laos and other countries. Its ingredients are basically the same as the original drug, and its efficacy is relatively stable. The price is only more than 2,000 yuan, which significantly reduces the cost of medication for patients.

Overall, the medical insurance coverage of capmatinib in my country is a positive signal, which means that more patients can obtain treatment through formal channels at a lower cost. However, in the transitional stage when drug supply is not yet fully popularized, purchasing drugs overseas is still a realistic choice for some patients. It is recommended that patients choose regular channels to purchase medicines under the guidance of doctors and ensure the quality and safety of medicines.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib